No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SON240719C50000
- 1.42
- -0.88-38.26%
15min DelayClose Jun 28 16:00 ET
1.65High1.42Low
1.65Open2.30Pre Close4 Volume25 Open Interest50.00Strike Price637.00Turnover19.53%IV1.38%PremiumJul 19, 2024Expiry Date0.72Intrinsic Value100Multiplier19DDays to Expiry0.70Extrinsic Value100Contract SizeAmericanOptions Type0.6560Delta0.1607Gamma36.23Leverage Ratio-0.0265Theta0.0170Rho23.77Eff Leverage0.0431Vega
Intraday
- 5D
- Daily
News
Reliable Income? Top Stocks With Decades Of Dividend Growth
Seaport Global Maintains Sonoco Products(SON.US) With Buy Rating, Maintains Target Price $65
Seaport Global analyst Mark Weintraub maintains $Sonoco Products(SON.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 74.1% a
Citi Maintains Sonoco Products(SON.US) With Buy Rating, Maintains Target Price $64
Citi analyst Anthony Pettinari maintains $Sonoco Products(SON.US)$ with a buy rating, and maintains the target price at $64.According to TipRanks data, the analyst has a success rate of 66.5% and a to
BofA Securities Maintains Sonoco Products(SON.US) With Buy Rating, Maintains Target Price $64
BofA Securities analyst George Staphos maintains $Sonoco Products(SON.US)$ with a buy rating, and maintains the target price at $64.According to TipRanks data, the analyst has a success rate of 52.5%
BofA Securities Maintains Sonoco Products(SON.US) With Buy Rating, Announces Target Price $64
BofA Securities analyst George Staphos maintains $Sonoco Products(SON.US)$ with a buy rating, and sets the target price at $64.According to TipRanks data, the analyst has a success rate of 52.5% and a
Wells Fargo Maintains Sonoco Products(SON.US) With Hold Rating
Wells Fargo analyst Gabrial Hajde maintains $Sonoco Products(SON.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 55.3% and a total average return of 2.6% over the
Comments
Despite recent insider selling at Sonoco Products, shareholders need not worry deeply as insiders retain considerable company ownership, suggesting alignment with shareholders. Notably, the buying activity over the past year signals insider enthusiasm.
One Sonoco Products Insider Raised Stake By 99% In Previous YearSonoco's decent ROE comes with high debt levels, indicating risk. High ROEs without excessive debt denote good quality. Among companies with similar debt-to-equity ratios, a higher ROE is preferable.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Oak Street Health(OSH.US$ -up 26.6%
2. $Baidu(BIDU.US$ -up 7.5%
3. $BP PLC(BP.US$ -up 3.2%
4. $Fiserv(FISV.US$ -up 2.4%
5. $Mitsubishi UFJ Financial Group(MUFG.US$ -up 1.4%
6. $GlaxoSmithKline(GSK.US$ -up 0.8%
7. $Microsoft(MSFT.US$ -up 0.7%
8. $Sanofi(SNY.US$ -up 0.5%
9. $Activision Blizzard(ATVI.US$ -up 0.4% ...
Gap Ups
1. $Oak Street Health(OSH.US$ -up 26.6%
2. $Baidu(BIDU.US$ -up 7.5%
3. $BP PLC(BP.US$ -up 3.2%
4. $Fiserv(FISV.US$ -up 2.4%
5. $Mitsubishi UFJ Financial Group(MUFG.US$ -up 1.4%
6. $GlaxoSmithKline(GSK.US$ -up 0.8%
7. $Microsoft(MSFT.US$ -up 0.7%
8. $Sanofi(SNY.US$ -up 0.5%
9. $Activision Blizzard(ATVI.US$ -up 0.4% ...
+15
8
Gapping up
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
6
Upgrades
• $Coupang(CPNG.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
• $Coupang(CPNG.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
14
Read more